IceCure's ProSense® Shows Strong Kidney Cancer Efficacy, Drives Breast Cryoablation Interest at ECIO 2026
ICCM is trading near its 52-week low of $0.217 (3.7% above the low).
Summary
IceCure Medical reported strong clinical data for its ProSense® cryoablation system in kidney and breast cancer, alongside significant interest and an overbooked master class at a major European oncology conference.
Key Events · Product Development and Regulatory · ICCM
-
Strong Kidney Cancer Efficacy
The ICESECRET trial's final analysis reported an 89.4% recurrence-free rate for kidney tumors ≤3cm treated with ProSense®, with 83.9% of patients remaining recurrence-free at a median follow-up of 4.0 years.
-
Positive Breast Cancer Outcomes
An independent study on early-stage breast cancer showed no residual disease at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes.
-
Significant Fibroadenoma Reduction
Another independent study demonstrated a 92.9% reduction in fibroadenoma volume at 12 months post-treatment using ProSense®.
-
High Interest at ECIO 2026
ProSense® was prominently featured at the European Conference on Interventional Oncology (ECIO 2026), including the first-ever dedicated breast cryoablation master class which was overbooked due to high demand.
Analysis · ICCM · Industrial Applications And Services
This filing provides crucial positive clinical updates for IceCure Medical, a company that recently disclosed a "going concern" warning. The strong recurrence-free rates for kidney cancer from the ICESECRET trial, coupled with excellent outcomes in breast cancer and fibroadenoma studies, validate the efficacy of their ProSense® technology. The high interest and overbooked master class at ECIO 2026 demonstrate growing commercial momentum and physician adoption, which are vital for the company's long-term viability and ability to secure future financing. This news could significantly boost investor confidence following recent financial concerns, especially as the stock trades near its 52-week low.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 37.5% of the 937 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICCM was trading at $0.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.22 to $1.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.